Implementation of a clinical decision-making tool for perioperative management of vitamin K antagonists in patients with atrial fibrillation

Perioperative management of anticoagulant treatment, such as vitamin K antagonists (VKA) and direct oral anticoagulants (DOAC), is challenging. The risk of perioperative bleeding and thromboembolic complications is determined by both patient and procedure-related factors, thus the individual-based periprocedural management of oral anticoagulant treatment often requires a multidisciplinary approach. Previous guidelines recommended patients on VKA treatment at high risk of thromboembolic complications to receive low-molecular-weight heparin (LMWH) at therapeutic dose during the period of interruption of oral anticoagulant treatment, also known as bridging [1,2].
Source: Thrombosis Research - Category: Hematology Authors: Tags: Letter to the Editors-in-Chief Source Type: research